Drug Shortage Report for LEVOTHYROXINE SODIUM FOR INJECTION

Last updated on 2023-07-20 History
Report ID 187645
Drug Identification Number 02245948
Brand name LEVOTHYROXINE SODIUM FOR INJECTION
Common or Proper name LEVOTHYROXINE SODIUM FOR INJECTION
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) LEVOTHYROXINE SODIUM
Strength(s) 500MCG
Dosage form(s) POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR
Packaging size 10mL
ATC code H03AA
ATC description THYROID PREPARATIONS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2023-03-31
Actual start date 2023-03-31
Estimated end date 2023-06-15
Actual end date 2023-06-16
Shortage status Resolved
Updated date 2023-07-20
Company comments Levothyroxine Sodium Injection 100 mcg/mL SD Vial 5 mL is available for substitution.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v5 2023-07-20 French Compare
v4 2023-07-20 English Compare
v3 2023-04-01 English Compare
v2 2023-03-22 French Compare
v1 2023-03-22 English Compare

Showing 1 to 5 of 5